Low Dose Atropine for Symptomatic Vitreous Floaters

Phase 2

Not yet recruiting

• Conditions: Vitreous Floaters
• Interventions: Drug: 0.01% atropine ophthalmic drop

• Registration Number: NCT06174935
• Lead Sponsor: Jeanette Du

Brief Summary

The objective of this study is to identify a potential pharmacologic option by assessing whether 0.01% atropine may be effective for treating bothersome floaters as measured by scores on a modified NEI VFQ-25.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-11-28
• Status Verified: 2023-12
• Study First Submitted QC: 2023-12-08
• Last Update Submitted: 2023-12-08
• Study First Posted: 2023-12-18
• Last Update Posted: 2023-12-18
• Study Start: 2024-01-01
• Primary Completion: 2024-06-01
• Study Completion: 2024-06-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Adult patients within Prism Vision Group with ICD diagnosis of acute posterior vitreous detachment and none of the ocular comorbidities listed as exclusion criteria will be screened as potential study participants.

Exclusion Criteria

• Patients with vitreous hemorrhage, other significant media opacity or vitreoretinal pathology, or history of pars plana vitrectomy will be excluded.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Atropine 0.01%	0.01% atropine ophthalmic drop	Patients will apply 1 drop daily of atropine 0.01%

Primary Outcome Measures

Name	Time	Method
Symptom improvement assessed by questionnaire	Up to 2 months	NEI VFQ-25 = National Eye Institute Visual Function Questionnaire

Trial Locations

Locations (1)

Retina Group of Washington; 🇺🇸 Reston, Virginia, United States